Barclays PLC Reaffirms “Overweight” Rating for AstraZeneca plc (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “overweight” rating reissued by equities researchers at Barclays PLC in a note issued to investors on Wednesday. They presently have a GBX 6,300 ($83.10) price objective on the biopharmaceutical company’s stock. Barclays PLC’s price objective suggests a potential upside of 37.89% from the stock’s previous close.
A number of other equities research analysts have also recently commented on AZN. UBS AG set a GBX 5,150 ($67.93) price target on shares of AstraZeneca plc and gave the stock a “neutral” rating in a report on Wednesday, April 5th. J P Morgan Chase & Co restated a “neutral” rating on shares of AstraZeneca plc in a report on Friday, July 21st. Shore Capital restated a “sell” rating on shares of AstraZeneca plc in a report on Sunday, April 2nd. Liberum Capital restated a “buy” rating and issued a GBX 5,500 ($72.55) price target on shares of AstraZeneca plc in a report on Wednesday, June 14th. Finally, BNP Paribas restated a “neutral” rating on shares of AstraZeneca plc in a report on Friday, July 21st. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of GBX 5,085.05 ($67.08).
Shares of AstraZeneca plc (LON AZN) traded up 1.95% during trading on Wednesday, reaching GBX 4569.00. 4,251,800 shares of the company were exchanged. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00. The stock’s 50-day moving average is GBX 5,140.37 and its 200-day moving average is GBX 4,862.43. The firm’s market cap is GBX 57.84 billion.
In related news, insider Nazneen Rahman acquired 39 shares of the stock in a transaction on Thursday, July 27th. The shares were acquired at an average price of GBX 4,370 ($57.64) per share, with a total value of £1,704.30 ($2,248.12).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.